- Home
- AVIR vs SPXX Comparison
AVIR vs SPXX Comparison
Compare AVIR & SPXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- SPXX
- Stock Information
- Founded
- AVIR 2012
- SPXX 2004
- Country
- AVIR United States
- SPXX United States
- Employees
- AVIR N/A
- SPXX N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- SPXX Trusts Except Educational Religious and Charitable
- Sector
- AVIR Health Care
- SPXX Finance
- Exchange
- AVIR Nasdaq
- SPXX Nasdaq
- Market Cap
- AVIR 284.6M
- SPXX 302.8M
- IPO Year
- AVIR 2020
- SPXX N/A
- Fundamental
- Price
- AVIR $3.24
- SPXX $17.87
- Analyst Decision
- AVIR Hold
- SPXX
- Analyst Count
- AVIR 1
- SPXX 0
- Target Price
- AVIR $6.88
- SPXX N/A
- AVG Volume (30 Days)
- AVIR 505.9K
- SPXX 51.3K
- Earning Date
- AVIR 02-26-2025
- SPXX 01-01-0001
- Dividend Yield
- AVIR N/A
- SPXX 7.55%
- EPS Growth
- AVIR N/A
- SPXX N/A
- EPS
- AVIR N/A
- SPXX N/A
- Revenue
- AVIR N/A
- SPXX N/A
- Revenue This Year
- AVIR N/A
- SPXX N/A
- Revenue Next Year
- AVIR N/A
- SPXX N/A
- P/E Ratio
- AVIR N/A
- SPXX N/A
- Revenue Growth
- AVIR N/A
- SPXX N/A
- 52 Week Low
- AVIR $2.75
- SPXX $13.57
- 52 Week High
- AVIR $4.60
- SPXX $16.05
- Technical
- Relative Strength Index (RSI)
- AVIR 47.81
- SPXX 60.29
- Support Level
- AVIR $3.11
- SPXX $17.03
- Resistance Level
- AVIR $3.49
- SPXX $17.81
- Average True Range (ATR)
- AVIR 0.14
- SPXX 0.25
- MACD
- AVIR -0.00
- SPXX 0.03
- Stochastic Oscillator
- AVIR 26.58
- SPXX 91.30
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About SPXX Nuveen S&P 500 Dynamic Overwrite Fund
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio (with a 55% long-term target) in an effort to enhance the Fund's risk-adjusted returns.